MoneyWorks4Me

Lupin concludes USFDA inspection at Aurangabad facility with one observation

31 Jul 2017 Evaluate

Lupin has successfully completed a PAI inspection (Prior Approval Inspection) carried out by the United States Food and Drug Administration (USFDA) at its Aurangabad manufacturing facility with one 483 observation. The observation was procedural in nature and corrected during the inspection itself.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Peers
Company Name CMP
Sun Pharma. Inds. 1810.00
Dr. Reddys Labs. 1200.10
Cipla 1346.85
Lupin 2029.00
Zydus Lifesciences 1145.25
View more..